Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 Data - Community Chart Signals

Live News

As of April 23, 2026, two key near-term catalysts have shifted investor sentiment for Amgen ahead of its upcoming quarterly earnings print. On April 6, the company announced statistically significant positive topline results from a Phase 3 trial evaluating a subcutaneous on-body injector formulation of TEPEZZA, its blockbuster treatment for moderate-to-severe active thyroid eye disease (TED). The trial met its primary endpoint of proptosis (eye bulge) response at 24 weeks, alongside all key seco Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataMany investors now incorporate global news and macroeconomic indicators into their market analysis. Events affecting energy, metals, or agriculture can influence equities indirectly, making comprehensive awareness critical.Monitoring macroeconomic indicators alongside asset performance is essential. Interest rates, employment data, and GDP growth often influence investor sentiment and sector-specific trends.Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataVisualization of complex relationships aids comprehension. Graphs and charts highlight insights not apparent in raw numbers.

Key Highlights

Three core takeaways stand out for current and prospective AMGN investors. First, the subcutaneous TEPEZZA Phase 3 trial delivered robust, clinically meaningful efficacy: the 77% proptosis response rate for the subQ formulation was more than 3.9 times the 19.6% rate recorded for the placebo arm, with a mean 3.17mm reduction in eye bulge versus 0.80mm for placebo. The subQ delivery method, which matches the efficacy of the existing IV formulation, will expand access to TED patients by eliminating Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataObserving trading volume alongside price movements can reveal underlying strength. Volume often confirms or contradicts trends.Some traders focus on short-term price movements, while others adopt long-term perspectives. Both approaches can benefit from real-time data, but their interpretation and application differ significantly.Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataInvestors often rely on a combination of real-time data and historical context to form a balanced view of the market. By comparing current movements with past behavior, they can better understand whether a trend is sustainable or temporary.

Expert Insights

From a fundamental analysis perspective, Amgen’s near-term risk-reward profile is balanced, supporting Guggenheim’s Neutral rating even as the stock screens as undervalued relative to historical and peer benchmarks. The bull case for AMGN is anchored in the upcoming TEPEZZA subQ launch, which is expected to add $400 to $600 million in annual incremental revenue by 2028, according to consensus sell-side estimates, as it captures 30% of new TED patient starts within 18 months of expected FDA approval in late 2026. Additionally, Amgen’s diversified pipeline of 19 late-stage assets across oncology, cardiovascular, and rare disease indications reduces single-asset risk, while its $18 billion share repurchase program authorized in 2025 provides ongoing support for share prices. That said, material downside risks limit upside in the near term: upcoming patent expiries for key drugs including Prolia and Xgeva in 2027 are expected to erase roughly $1.8 billion in annual revenue by 2029, absent offsetting pipeline wins, while competitive pressure from new GLP-1 cardiovascular therapies could weigh on sales of Amgen’s Repatha franchise. Guggenheim’s $351 price target implies a 4.8% upside from AMGN’s April 23 closing price of $334.92, a relatively modest total return compared to higher-growth segments of the market. As noted in Insider Monkey’s market coverage, select undervalued AI equities offer significantly higher upside potential in the current market cycle, with lower downside risk tied to onshoring trends and Trump-era tariff policies that support domestic AI hardware and software manufacturing. For investors with a moderate risk tolerance and focus on defensive, income-generating equities, AMGN remains a compelling hold at current levels, with the upcoming Q1 earnings release offering a catalyst for upward re-rating if the company delivers on consensus revenue estimates of $7.2 billion and adjusted EPS of $4.52. For growth-oriented investors, however, allocations to niche AI equities may generate superior risk-adjusted returns over the 12-month investment horizon. Investors should monitor Amgen’s Q1 earnings call for management guidance on the TEPEZZA subQ launch timeline, as well as updates on pipeline progress for its lead KRAS inhibitor sotorasib, which is being evaluated in expanded first-line lung cancer indications. Disclosure: No positions held in AMGN or related derivatives at the time of publication. (Word count: 1172) Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataSome traders rely on alerts to track key thresholds, allowing them to react promptly without monitoring every minute of the trading day. This approach balances convenience with responsiveness in fast-moving markets.Correlating global indices helps investors anticipate contagion effects. Movements in major markets, such as US equities or Asian indices, can have a domino effect, influencing local markets and creating early signals for international investment strategies.Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataVolatility can present both risks and opportunities. Investors who manage their exposure carefully while capitalizing on price swings often achieve better outcomes than those who react emotionally.